eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
6/2024
vol. 41
 
Share:
Send email
Share:
abstract:
Original paper

Significance of HLA-B*15 in three pemphigus patients with rituximab-triggered severe cutaneous drug reactions

Tang Jun-ting
1
,
Tu Ying
1
,
Sun Dong-Jie
1
,
Nong Xiang
1
,
Cao Can
1
,
Du Si-Cheng
1
,
Cun Yue-Ting
1
,
He Li
1

  1. Department of Dermatology and Venerology, First Affiliated Hospital of Kunming Medical University, Kunming, China
Adv Dermatol Allergol 2024; XLI (6): 566-570
DOI: https://doi.org/10.5114/ada.2024.145439
Online publish date: 2024/12/02
View full text Get citation
 
Introduction:
Rituximab, a CD20 inhibitor, has swiftly become the primary treatment for pemphigus patients.

Aim:
We present 3 cases of pemphigus patients who had undergone rituximab treatment.

Material and methods:
After the second intravenous administration of rituximab, the primary rash developed into severe cutaneous drug reactions. Peripheral blood was collected from the aforementioned 3 patients for the detection of susceptibility genes by using second-generation sequencing.

Results:
Notably, a significant resemblance was observed in the HLA profiles of these 3 patients, particularly regarding high-risk alleles associated with rituximab-induced severe cutaneous drug reactions (CDRs). This rare occurrence of severe CDRs post-rituximab administration may be HLA-dependent and linked to HLA-B*15:02:01, HLA-B*15:12 and HLA-B*15:27:01. This pioneering laboratory trial shows the pathological background of rituximab-induced severe cutaneous drug reactions.

Conclusions:
Our findings contribute to the expanding catalogue of potential HLA-B*15 linked to severe CDRs and underscore the importance of vigilance regarding such reactions in pemphigus patients undergoing rituximab therapy.

keywords:

pemphigus, rituximab, severe cutaneous drug reactions, HLA
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.